JNJ-2761
/ J&J
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 04, 2025
Discovery of JNJ-87562761, a novel anti-GPRC5D enhanced effector function (eEF) antibody with multiple mechanisms of action for the treatment of multiple myeloma
(ASH 2025)
- P1 | "JNJ-87562761 demonstrated potent in vitro activity with 3 distinct mechanisms as well aspotent in vivo activity in 2 MM xenograft models. The safety and preliminary efficacy of JNJ-87562761 iscurrently being evaluated in a Phase 1 study of participants with relapsed/refractory MM (NCT06604715)."
IO biomarker • Hematological Malignancies • Multiple Myeloma • GPRC5D • IL15
December 20, 2024
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Janssen Research & Development, LLC | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2027 ➔ Nov 2028
Enrollment open • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology
September 20, 2024
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=80 | Not yet recruiting | Sponsor: Janssen Research & Development, LLC
New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 3
Of
3
Go to page
1